Clover Biopharmaceuticals Limited (“Shamus Bio-B”) filed with Hong Kong Trading and Clearing Limited on 6 May 2024 an updated Monthly Statement of Changes in Securities Reporting for the year ended 30 April 2024. The report showed that the company's regulated/registered capital deposit remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, with no increase or decrease this month. However, in terms of the details of the changes in the issued shares, the company issued 52,000 new shares under the share option scheme during the month as a result of the exercise of the share options and as a result received HK$416. The share option plan is divided into two plans before and after the initial public offering...Show More

Clover Biopharmaceuticals Limited (“Shamus Bio-B”) filed with Hong Kong Trading and Clearing Limited on 6 May 2024 an updated Monthly Statement of Changes in Securities Reporting for the year ended 30 April 2024. The report showed that the company's regulated/registered capital deposit remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, with no increase or decrease this month. However, in terms of the details of the changes in the issued shares, the company issued 52,000 new shares under the share option scheme during the month as a result of the exercise of the share options and as a result received HK$416. The share option plan is divided into two plans before and after the initial public offering, which were approved by the General Meeting on April 15 and September 26, 2021, respectively. During this month, 52,000 share options were exercised under the Initial Public Offering pre-IPO share option plan, and 6,993,573 share options expired under the Initial Public Offering post-IPO share option plan. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.